1. [CASE 1 — QUESTION 1]
A 7-year-old boy is receiving induction chemotherapy for acute lymphoblastic leukemia (ALL) that includes weekly intravenous vincristine. Over the past three weeks his parents report increasing constipation, and at this visit he has trouble climbing onto the examination table. On examination, both ankle deep tendon reflexes are absent and he has distal sensory changes in the feet, though strength remains largely preserved. He is afebrile and his complete blood count is acceptable for this point in therapy. Which interpretation and next step is most appropriate?
A) The findings reflect leukemic meningeal infiltration and require urgent intrathecal chemotherapy escalation
B) The findings indicate vincristine myelosuppression, and therapy should be held for neutropenia
C) The findings reflect cumulative vincristine neurotoxicity, the drug's dose-limiting toxicity, and the vincristine dose should be reduced or delayed with continued serial neurologic monitoring
D) The findings are unrelated to vincristine and warrant only reassurance
E) The findings represent an acute hypersensitivity reaction requiring permanent discontinuation of all chemotherapy
ANSWER: C
Rationale:
Loss of ankle deep tendon reflexes with distal sensory changes and autonomic constipation is the classic early, length-dependent presentation of cumulative vincristine neurotoxicity, which is vincristine's dose-limiting toxicity rather than myelosuppression. Because the neuropathy is cumulative and only partially reversible, the appropriate response is dose reduction or delay with continued serial neurologic examination before each dose, detecting progression before motor deficits become disabling.
Option A: Option A is incorrect: a symmetric distal sensory pattern with lost reflexes fits drug neuropathy, not meningeal leukemic infiltration requiring intrathecal escalation.
Option B: Option B is incorrect: vincristine's dose-limiting toxicity is neuropathy, not myelosuppression, and the blood count is acceptable.
Option D: Option D is incorrect: these are recognizable vincristine neurotoxicity findings that require dose modification, not reassurance alone.
Option E: Option E is incorrect: this is a dose-related toxicity managed by modification and monitoring, not an allergic reaction mandating permanent cessation of all chemotherapy.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient. While vincristine is continued at a modified dose, he develops oropharyngeal candidiasis, and the covering team proposes starting oral itraconazole. The oncology pharmacist reviews the plan before the antifungal is dispensed. Which recommendation is most appropriate?
A) Avoid itraconazole if possible and select an antifungal strategy that does not strongly inhibit CYP3A4 (cytochrome P450 3A4), because itraconazole inhibition of CYP3A4 will increase vincristine exposure and neurotoxicity risk
B) Start itraconazole and increase the vincristine dose to preserve antileukemic efficacy
C) Start itraconazole and add granulocyte colony-stimulating factor to prevent the expected toxicity
D) Proceed without concern, because vincristine is eliminated unchanged by the kidney
E) Discontinue vincristine permanently, because any azole exposure causes irreversible myelosuppression
ANSWER: A
Rationale:
Vincristine is metabolized by CYP3A4 and is a P-glycoprotein substrate. Itraconazole is a strong CYP3A4 inhibitor, so combining the two reduces vincristine metabolism, increases exposure, and raises the risk of severe neurotoxicity, a particular concern in a child already showing early neuropathy. The appropriate step is to avoid the interacting azole where feasible and use an antifungal approach that does not strongly inhibit CYP3A4.
Option B: Option B is incorrect: increasing the vincristine dose while inhibiting its metabolism compounds the exposure increase and neurotoxicity risk.
Option C: Option C is incorrect: the dominant toxicity from increased vincristine exposure is neuropathy, which granulocyte colony-stimulating factor does not prevent.
Option D: Option D is incorrect: vincristine is hepatically metabolized by CYP3A4, not renally eliminated unchanged, so the interaction is real.
Option E: Option E is incorrect: the azole interaction increases neurotoxicity through CYP3A4 inhibition, not irreversible myelosuppression, and permanent discontinuation is not the correct framing.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient. Two weeks later he is noted to be mildly lethargic, and laboratory studies show a serum sodium of 123 mEq/L with low serum osmolality, a urine osmolality of 340 mOsm/kg, and clinically normal volume status. He has no seizures. Which mechanism and initial management is most appropriate?
A) Cerebral salt wasting with true volume depletion, managed with aggressive isotonic saline repletion
B) Diabetes insipidus, managed with desmopressin
C) Pseudohyponatremia from a laboratory artifact, requiring no intervention
D) Adrenal insufficiency, managed with stress-dose corticosteroids
E) Vincristine-associated SIADH (syndrome of inappropriate antidiuretic hormone secretion) producing euvolemic hyponatremia, managed initially with fluid restriction and a controlled correction rate
ANSWER: E
Rationale:
Euvolemic hyponatremia with low serum osmolality and inappropriately concentrated urine is the syndrome of inappropriate antidiuretic hormone secretion (SIADH), a recognized vincristine effect from disruption of the hypothalamic-neurohypophyseal axis. With mild symptoms, initial management is fluid restriction with attention to a safe rate of correction, reserving controlled hypertonic saline for severe or clearly symptomatic hyponatremia.
Option A: Option A is incorrect: this patient is euvolemic, whereas cerebral salt wasting involves true volume depletion, and saline loading does not correct SIADH.
Option B: Option B is incorrect: diabetes insipidus produces dilute urine and a tendency to hypernatremia, the opposite of this concentrated-urine, hyponatremic picture.
Option C: Option C is incorrect: pseudohyponatremia shows normal serum osmolality, whereas this patient has genuinely low osmolality.
Option D: Option D is incorrect: adrenal insufficiency typically produces additional features such as hyperkalemia and hypotension and does not fit a euvolemic, concentrated-urine SIADH pattern.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient. During a case review, a trainee asks why vincristine dosing carries a notable risk of inadvertent overdose compared with many other cytotoxic drugs. Which explanation is correct?
A) Vincristine has a narrow renal clearance threshold that frequently triggers dose-limiting accumulation
B) Vincristine has essentially no upper dose ceiling based on bone marrow tolerance, because its dose-limiting toxicity is neurotoxicity rather than myelosuppression, so the usual marrow-based safety brake does not flag an excessive dose
C) Vincristine has a fixed maximum cumulative cardiac dose analogous to the anthracyclines, which is easy to exceed
D) Vincristine must be dose-reduced for every patient based on a drug-unique body surface area limit
E) Vincristine overdose risk arises because it is a prodrug requiring tumor-specific activation
ANSWER: B
Rationale:
Because vincristine's dose-limiting toxicity is peripheral neurotoxicity rather than myelosuppression, it has essentially no upper dose ceiling based on bone marrow tolerance. The marrow suppression that normally limits many cytotoxic agents does not act as a brake here, so an erroneously high dose is not flagged by the marrow, making inadvertent overdose a real clinical risk and the reason institutional dose caps and verification steps are emphasized.
Option A: Option A is incorrect: vincristine is hepatically metabolized by CYP3A4, and a renal clearance threshold does not cap its dosing.
Option C: Option C is incorrect: a fixed cumulative cardiac dose ceiling characterizes the anthracyclines, not vincristine.
Option D: Option D is incorrect: there is no drug-unique body surface area rule mandating universal dose reduction.
Option E: Option E is incorrect: vincristine is not a prodrug requiring tumor-specific activation; its overdose risk stems from the absence of a marrow-based dose ceiling.
5. [CASE 2 — QUESTION 1]
A 60-year-old woman with newly diagnosed advanced ovarian cancer is starting first-line therapy with conventional (Cremophor EL-based) paclitaxel followed by carboplatin. She received the standard premedication. About 5 minutes into her first paclitaxel infusion she develops facial flushing, dyspnea with audible wheezing, and a fall in blood pressure to 82/48 mmHg. Which immediate action is most appropriate?
A) Slow the infusion modestly and continue, because a premedicated patient cannot have a clinically significant reaction
B) Switch immediately to docetaxel mid-infusion to bypass the reaction
C) Administer a CYP2C8 (cytochrome P450 2C8) inhibitor to slow paclitaxel metabolism and blunt the reaction
D) Stop the paclitaxel infusion immediately and provide supportive care (airway support, intravenous fluids, antihistamines, and corticosteroids, with epinephrine if severe), recognizing a Cremophor EL anaphylactoid reaction
E) Continue the infusion and send beta-III tubulin testing to identify the cause
ANSWER: D
Rationale:
Flushing, bronchospasm, and hypotension within the first minutes of a conventional paclitaxel infusion is the classic Cremophor EL anaphylactoid reaction. It is non-IgE-mediated and can occur despite premedication, so the immediate action is to stop the infusion and provide supportive care, escalating to epinephrine for severe reactions; many patients can later be rechallenged at a slower rate after stabilization and additional antihistamine and corticosteroid.
Option A: Option A is incorrect: premedication reduces but does not eliminate reactions, and continuing through hypotension and bronchospasm is unsafe.
Option B: Option B is incorrect: switching agents mid-infusion during an acute reaction is not appropriate management; stabilize the patient first.
Option C: Option C is incorrect: the reaction is vehicle-mediated and anaphylactoid, not a metabolism problem a CYP2C8 inhibitor would address.
Option E: Option E is incorrect: the cause is already evident as a Cremophor anaphylactoid reaction, and continuing the infusion to pursue tubulin testing endangers the patient.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient. After she is stabilized, the team reviews the standard premedication regimen used to reduce severe hypersensitivity reactions to conventional paclitaxel before any future attempt. Which three-drug combination is the standard premedication?
A) A corticosteroid (dexamethasone), an H1 (histamine type 1) antihistamine (diphenhydramine), and an H2 (histamine type 2) antagonist (such as ranitidine or cimetidine)
B) Epinephrine, inhaled albuterol, and hydrocortisone given prophylactically before every dose
C) Acetaminophen, an H1 antihistamine, and ondansetron
D) Two H1 antihistamines plus a leukotriene receptor antagonist
E) A proton pump inhibitor, a corticosteroid, and aprepitant
ANSWER: A
Rationale:
The standard premedication for conventional paclitaxel combines a corticosteroid, an H1 antihistamine, and an H2 antagonist: dexamethasone (for example at 12 and 6 hours before infusion), diphenhydramine, and an H2 antagonist such as ranitidine or cimetidine about 30 minutes before infusion. Each targets a distinct component of the Cremophor EL anaphylactoid reaction, with the corticosteroid the most important; together they reduce severe reactions to roughly 1 to 2%.
Option B: Option B is incorrect: epinephrine and albuterol treat an established reaction and are not the scheduled premedication.
Option C: Option C is incorrect: acetaminophen and ondansetron do not address the histamine-mediated hypersensitivity the protocol targets.
Option D: Option D is incorrect: the regimen pairs an H1 with an H2 antagonist and a corticosteroid, not two H1 agents plus a leukotriene blocker.
Option E: Option E is incorrect: a proton pump inhibitor and aprepitant are not the standard hypersensitivity premedication.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient. When conventional paclitaxel is reattempted at a slower rate, the nurse confirms the administration equipment. Which tubing requirement applies, and why?
A) Standard polyvinyl chloride (PVC) tubing is preferred because it binds excess drug and prevents overdose
B) Glass-lined tubing is required because paclitaxel degrades on contact with any plastic
C) Non-PVC tubing is required, because the Cremophor EL vehicle leaches DEHP (di(2-ethylhexyl) phthalate) plasticizer from PVC tubing at clinically significant concentrations
D) Any tubing is acceptable, because the vehicle does not interact with tubing materials
E) A special antimicrobial-coated tubing is required to prevent line infection unique to paclitaxel
ANSWER: C
Rationale:
Conventional paclitaxel must be infused through non-PVC tubing because its Cremophor EL (polyoxyethylated castor oil) vehicle leaches DEHP (di(2-ethylhexyl) phthalate) plasticizer from polyvinyl chloride tubing at clinically significant concentrations. This is the same vehicle responsible for the anaphylactoid hypersensitivity reactions, tying both administration precautions to a single cause.
Option A: Option A is incorrect: the concern is DEHP entering the patient from PVC, not drug binding that would cause underdosing, and PVC is specifically avoided.
Option B: Option B is incorrect: the issue is plasticizer leaching, not paclitaxel degradation requiring glass tubing.
Option D: Option D is incorrect: the Cremophor EL vehicle does interact with PVC by extracting DEHP, so tubing choice matters.
Option E: Option E is incorrect: the requirement is driven by DEHP leaching, not infection control.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient. In planning her combination chemotherapy, the team recalls the well-described sequence-dependent interaction between paclitaxel and cisplatin. Regarding paclitaxel and cisplatin specifically, which statement about administration sequence is correct?
A) The sequence has no measurable effect on paclitaxel pharmacokinetics or toxicity
B) Giving paclitaxel before cisplatin preserves higher paclitaxel clearance and produces lower toxicity, whereas giving cisplatin first impairs hepatic paclitaxel metabolism, lowering clearance and increasing toxicity
C) Giving cisplatin before paclitaxel increases paclitaxel clearance and decreases its toxicity
D) Paclitaxel chemically inactivates cisplatin in the bloodstream, which is why paclitaxel must be given first
E) The sequence matters only for cisplatin nephrotoxicity and is unrelated to paclitaxel handling
ANSWER: B
Rationale:
The paclitaxel-cisplatin interaction is sequence-dependent with a direct toxicity consequence. When cisplatin is given first, it impairs hepatic metabolism of paclitaxel, lowering paclitaxel clearance and increasing its toxicity. Giving paclitaxel before cisplatin preserves higher paclitaxel clearance and yields lower toxicity, which is why paclitaxel-first is the standard sequence in many protocols.
Option A: Option A is incorrect: the order does measurably affect paclitaxel pharmacokinetics and toxicity.
Option C: Option C is incorrect: it reverses the relationship, since cisplatin first lowers paclitaxel clearance and raises toxicity.
Option D: Option D is incorrect: the rationale is a metabolic pharmacokinetic effect, not chemical inactivation of cisplatin by paclitaxel.
Option E: Option E is incorrect: the interaction specifically concerns paclitaxel hepatic metabolism, not solely cisplatin nephrotoxicity.
9. [CASE 3 — QUESTION 1]
A 24-year-old man with lymphoma is scheduled to receive intrathecal methotrexate and intravenous vincristine on the same clinic day. In a preparation error, the vincristine intended for intravenous use is administered into the intrathecal space. The error is identified shortly afterward, before symptoms have developed. Regarding the expected natural history if no intervention is undertaken, which statement is correct?
A) A transient chemical meningitis that resolves fully with corticosteroids within days
B) A self-limited radiculopathy that recovers completely once the drug clears the cerebrospinal fluid
C) No clinical effect, because vinca alkaloids cannot injure central neurons from the cerebrospinal fluid
D) An ascending myeloencephalopathy that is nearly uniformly fatal within days to weeks
E) An immediate but fully reversible flaccid paralysis resolving within hours
ANSWER: D
Rationale:
Inadvertent intrathecal administration of a vinca alkaloid produces an ascending myeloencephalopathy that is nearly uniformly fatal within days to weeks. Direct intrathecal injection bypasses the blood-brain barrier that normally protects central neurons, and vinca alkaloids are profoundly neurotoxic in the cerebrospinal fluid. The course is stereotyped: severe radicular pain within hours, then ascending motor weakness, sphincter loss, and progressive paralysis ascending to the brain stem with respiratory failure and death.
Option A: Option A is incorrect: this is not a transient, fully reversible chemical meningitis; the injury is destructive and progressive.
Option B: Option B is incorrect: the syndrome does not self-resolve once the drug clears; neuronal destruction is irreversible.
Option C: Option C is incorrect: direct intrathecal injection bypasses the blood-brain barrier and is intensely neurotoxic, the opposite of having no effect.
Option E: Option E is incorrect: the paralysis is progressive and fatal, not a brief reversible episode.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient. The error is recognized within the first hour. Which immediate intervention offers the only described chance of limiting the injury?
A) Intravenous calcium with observation, since the syndrome is usually self-limited
B) Emergent cerebrospinal fluid (CSF) lavage with neurosurgical placement of a drain and exchange of as much CSF as feasible, combined with intrathecal instillation of fresh frozen plasma, the only described approach with rare partial survivors
C) A single dose of intravenous corticosteroids followed by discharge with outpatient follow-up
D) Systemic plasmapheresis as definitive therapy expected to fully reverse the injury
E) Reassurance only, because intrathecal vincristine causes a transient, fully reversible radiculopathy
ANSWER: B
Rationale:
The only intervention with rare partial survivors reported is immediate, aggressive cerebrospinal fluid (CSF) lavage through a neurosurgically placed drain, exchanging as much CSF as feasible, combined with intrathecal instillation of fresh frozen plasma (the plasma proteins bind the vinca alkaloid and reduce free drug). Recognition within the first hour is exactly when this attempt is most worthwhile, alongside immediate neurosurgical involvement, even though complete recovery has not been documented.
Option A: Option A is incorrect: the syndrome is progressive and usually fatal, not self-limited, so observation with calcium is inadequate.
Option C: Option C is incorrect: a single corticosteroid dose with discharge is grossly insufficient for this emergency.
Option D: Option D is incorrect: systemic plasmapheresis does not address drug already within the cerebrospinal fluid and is not the described rescue.
Option E: Option E is incorrect: the injury is progressive and life-threatening, not a transient reversible radiculopathy.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient. The institution convenes a safety review to prevent recurrence. Which single safeguard most directly makes intrathecal administration of a vinca alkaloid physically impossible?
A) Dispensing vinca alkaloids only in a minibag (for example 25 to 50 mL of normal saline) rather than in a syringe, which is physically incompatible with intrathecal administration hardware
B) Requiring a second nurse to verbally confirm the intended route before injection
C) Limiting vinca alkaloid dosing to a once-weekly schedule to reduce total exposure
D) Storing vinca alkaloids in a dedicated refrigerator apart from other chemotherapy
E) Requiring drug-specific written informed consent before each vinca alkaloid dose
ANSWER: A
Rationale:
The most direct engineering safeguard is to dispense vinca alkaloids only in a minibag rather than a syringe. Because intrathecal injections are given by syringe, a minibag is physically incompatible with intrathecal administration hardware, making the wrong-route error mechanically impossible. This is one of the four non-negotiable safeguards, alongside prominent For Intravenous Use Only labeling, sealed outer overpackaging, and separating intrathecal and intravenous procedures in time and location.
Option B: Option B is incorrect: verbal confirmation is a useful human check but relies on attention and does not physically prevent the error the way minibag packaging does.
Option C: Option C is incorrect: changing the dosing schedule does not address the route-of-administration error.
Option D: Option D is incorrect: a separate storage location does not physically prevent an intrathecal route error.
Option E: Option E is incorrect: informed consent addresses the decision to treat, not the physical prevention of a wrong-route administration.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient. The safety committee adopts all four mandated safeguards: minibag-only dispensing, prominent warning labeling, sealed outer overpackaging, and separation of intrathecal and intravenous procedures in time and location. A committee member asks why all four are required rather than relying on the single strongest one. Which statement best captures the combined design logic?
A) The four safeguards are interchangeable alternatives, so implementing any one alone is sufficient
B) The safeguards are intended mainly to speed drug preparation rather than to prevent route errors
C) The safeguards apply only in pediatric oncology and have no role in adult practice
D) The safeguards address the toxicity of the drug after it is injected intrathecally rather than preventing the wrong-route administration
E) The safeguards form a layered defense targeting the root cause, the physical co-presence of intrathecal syringes and intravenous vinca alkaloid preparations in the same place and time, with each layer addressing a different failure point
ANSWER: E
Rationale:
The four safeguards form a layered defense aimed at a single root cause: the physical co-presence of intrathecal syringes and intravenous vinca alkaloid preparations in the same clinical space at the same time. Minibag-only dispensing makes intrathecal injection physically impossible; warning labels and sealed overpackaging interrupt the error at the point of handling; and separating the procedures in time and location removes the opportunity for confusion. Because human and system failures can occur at different points, multiple layers are required, and failures have consistently occurred where implementation was incomplete.
Option A: Option A is incorrect: the layers are complementary, not interchangeable, and partial implementation has repeatedly failed.
Option B: Option B is incorrect: the purpose is error prevention, not preparation speed.
Option C: Option C is incorrect: the safeguards apply wherever intrathecal chemotherapy and intravenous vinca alkaloids coexist, in adult as well as pediatric care.
Option D: Option D is incorrect: the safeguards prevent the wrong-route administration; the syndrome itself has no reliable rescue, which is exactly why prevention is emphasized.
13. [CASE 4 — QUESTION 1]
A 70-year-old man with metastatic castration-resistant prostate cancer (CRPC) has progressed after docetaxel-based therapy. His oncologist wants a taxane that can overcome P-glycoprotein-mediated taxane resistance and asks about the appropriate supportive care. Which agent and supportive-care plan is best supported?
A) Re-treat with the same docetaxel regimen at a higher dose, since resistance is overcome by dose escalation alone
B) Use conventional paclitaxel, which is unaffected by P-glycoprotein efflux
C) Use cabazitaxel, a poor P-glycoprotein (P-gp) substrate that can act in P-gp-overexpressing cells, with primary granulocyte colony-stimulating factor (G-CSF) prophylaxis because of its high febrile neutropenia rate
D) Switch to a vinca alkaloid administered intrathecally to bypass systemic resistance
E) Begin ixabepilone with capecitabine regardless of liver function, since hepatic status does not affect this combination
ANSWER: C
Rationale:
Cabazitaxel was developed specifically to overcome P-glycoprotein (P-gp)-mediated taxane resistance: it is a poor P-gp substrate and can reach cytotoxic intracellular concentrations in P-gp-overexpressing cells. It is approved for castration-resistant prostate cancer after prior docetaxel, where it improved survival versus mitoxantrone. Because cabazitaxel causes febrile neutropenia at a substantially higher rate than docetaxel, primary granulocyte colony-stimulating factor (G-CSF) prophylaxis is recommended for all patients.
Option A: Option A is incorrect: re-treating with the same docetaxel regimen does not overcome P-gp resistance, and dose escalation alone is not the strategy.
Option B: Option B is incorrect: conventional paclitaxel is a P-gp substrate and is effluxed by P-gp, so it is affected by this resistance mechanism.
Option D: Option D is incorrect: intrathecal vinca alkaloid administration is fatal and is never a route for systemic therapy.
Option E: Option E is incorrect: ixabepilone with capecitabine is contraindicated in significant hepatic impairment, so disregarding liver function is unsafe.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient. His tumor's resistance is attributed to an efflux mechanism. Which resistance mechanism is the most broadly applicable across both the vinca alkaloid and taxane classes and across most hydrophobic anticancer drugs?
A) P-glycoprotein (P-gp) overexpression, encoded by ABCB1 (ATP-binding cassette subfamily B member 1, also called MDR1), an ATP-dependent efflux pump that exports paclitaxel, docetaxel, and the vinca alkaloids out of cells
B) A point mutation in the taxane-binding domain that affects only the taxanes
C) Beta-III tubulin overexpression, which is specific to vinca alkaloid resistance
D) Loss of the spindle assembly checkpoint, which makes cells hypersensitive rather than resistant
E) Upregulated renal tubular transporters that increase urinary excretion of the drug
ANSWER: A
Rationale:
P-glycoprotein (P-gp), encoded by the ABCB1 (also called MDR1) gene, is an ATP-dependent efflux pump that transports a broad range of hydrophobic substrates, including paclitaxel, docetaxel, vincristine, vinblastine, and vinorelbine, out of cells. By lowering intracellular drug accumulation below the cytotoxic threshold, it produces resistance spanning both major antimicrotubule classes and most hydrophobic anticancer drugs, making it the broadest applicable mechanism, and the reason agents that evade P-gp, such as cabazitaxel and ixabepilone, were developed.
Option B: Option B is incorrect: a taxane-binding-domain point mutation is a target-level mechanism specific to taxanes, not broadly cross-class.
Option C: Option C is incorrect: beta-III tubulin overexpression principally reduces taxane efficacy and is not specific to vinca alkaloid resistance as stated.
Option D: Option D is incorrect: loss of the spindle assembly checkpoint does not produce the broad efflux-based resistance described.
Option E: Option E is incorrect: increased renal transporter-mediated excretion is not the established broad antimicrotubule resistance mechanism; P-gp efflux at the tumor cell is.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient. A separate patient discussed at the same tumor board has metastatic breast cancer with high beta-III tubulin expression after taxane failure. Integrating the target-level basis of this resistance, which statement best guides drug selection?
A) Beta-III tubulin overexpression confers uniform resistance to every microtubule-targeting agent, so the entire class should be abandoned
B) Beta-III tubulin overexpression increases taxane binding affinity, so escalating the taxane dose is rational
C) Beta-III tubulin overexpression acts through P-glycoprotein efflux, so adding a P-gp inhibitor to the taxane is the definitive fix
D) Beta-III tubulin overexpression lowers taxane binding affinity and increases microtubule dynamics, but vinca alkaloids and ixabepilone are less affected, so switching to one of those agents is rational
E) Beta-III tubulin overexpression affects only the vinca alkaloids, so continuing the taxane unchanged is appropriate
ANSWER: D
Rationale:
Beta-III tubulin is the isotype with the lowest affinity for taxanes; its overexpression lowers paclitaxel binding affinity and yields more dynamic microtubules that taxanes suppress less effectively, producing target-level resistance associated with poor outcomes. Vinca alkaloids and ixabepilone are less affected by beta-III tubulin overexpression, so switching to one of those agents is a rational, mechanism-informed step.
Option A: Option A is incorrect: the resistance is selective, not uniform across the whole class, so abandoning all microtubule agents is unwarranted.
Option B: Option B is incorrect: beta-III overexpression lowers taxane affinity, so dose escalation of the same taxane is not rational.
Option C: Option C is incorrect: this is a tubulin-binding (target-level) mechanism, not P-gp efflux, so a P-gp inhibitor is not the targeted solution.
Option E: Option E is incorrect: it reverses the relationship, since beta-III overexpression principally reduces taxane efficacy while sparing vinca alkaloids.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient. For the breast cancer patient under discussion, the team considers ixabepilone combined with capecitabine. Her laboratory studies show AST (aspartate aminotransferase) at 3 times the upper limit of normal and bilirubin at 1.8 times the upper limit of normal. Which decision is most appropriate?
A) Proceed at full dose, since liver function does not affect this combination
B) Do not use ixabepilone with capecitabine in this patient, because hepatic impairment with AST or ALT (alanine aminotransferase) above 2.5 times the upper limit of normal, or bilirubin above 1.5 times the upper limit of normal, is a contraindication to this combination owing to markedly increased toxic deaths
C) Proceed with the combination after a single dose of corticosteroid, which neutralizes the hepatic risk
D) Proceed but add granulocyte colony-stimulating factor to offset the added risk
E) Substitute intrathecal ixabepilone to bypass hepatic metabolism
ANSWER: B
Rationale:
Hepatic impairment markedly increases ixabepilone exposure and toxicity. In combination with capecitabine, ixabepilone is contraindicated when AST or ALT exceeds 2.5 times the upper limit of normal, or bilirubin exceeds 1.5 times the upper limit of normal, because of markedly increased toxic deaths observed in hepatically impaired patients receiving this combination in clinical trials. This patient meets both thresholds, so the combination should not be used.
Option A: Option A is incorrect: hepatic function does affect this regimen, and the patient exceeds the contraindication thresholds.
Option C: Option C is incorrect: a corticosteroid does not neutralize the hepatic contraindication.
Option D: Option D is incorrect: granulocyte colony-stimulating factor does not address the hepatic-impairment-related toxic death risk that defines the contraindication.
Option E: Option E is incorrect: ixabepilone is given systemically; there is no intrathecal route, and intrathecal administration of microtubule agents is dangerous.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.